Novel glucagon-like peptide-1 (GLP-1) drugs were designed and industrially prepared by researchers at the Hefei Institutes of Physical Science of the Chinese Academy of Sciences through molecular design, strain construction, isolation and purification, and animal experiments, according to a paper published in Pharmaceuticals.